401 related articles for article (PubMed ID: 33431788)
21. CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas.
Jiang Y; Ortega-Molina A; Geng H; Ying HY; Hatzi K; Parsa S; McNally D; Wang L; Doane AS; Agirre X; Teater M; Meydan C; Li Z; Poloway D; Wang S; Ennishi D; Scott DW; Stengel KR; Kranz JE; Holson E; Sharma S; Young JW; Chu CS; Roeder RG; Shaknovich R; Hiebert SW; Gascoyne RD; Tam W; Elemento O; Wendel HG; Melnick AM
Cancer Discov; 2017 Jan; 7(1):38-53. PubMed ID: 27733359
[TBL] [Abstract][Full Text] [Related]
22. TET2 Deficiency Causes Germinal Center Hyperplasia, Impairs Plasma Cell Differentiation, and Promotes B-cell Lymphomagenesis.
Dominguez PM; Ghamlouch H; Rosikiewicz W; Kumar P; Béguelin W; Fontán L; Rivas MA; Pawlikowska P; Armand M; Mouly E; Torres-Martin M; Doane AS; Calvo Fernandez MT; Durant M; Della-Valle V; Teater M; Cimmino L; Droin N; Tadros S; Motanagh S; Shih AH; Rubin MA; Tam W; Aifantis I; Levine RL; Elemento O; Inghirami G; Green MR; Figueroa ME; Bernard OA; Aoufouchi S; Li S; Shaknovich R; Melnick AM
Cancer Discov; 2018 Dec; 8(12):1632-1653. PubMed ID: 30274972
[No Abstract] [Full Text] [Related]
23. Mutations in CREBBP and EP300 genes affect DNA repair of oxidative damage in Rubinstein-Taybi syndrome cells.
Dutto I; Scalera C; Tillhon M; Ticli G; Passaniti G; Cazzalini O; Savio M; Stivala LA; Gervasini C; Larizza L; Prosperi E
Carcinogenesis; 2020 May; 41(3):257-266. PubMed ID: 31504229
[TBL] [Abstract][Full Text] [Related]
24. BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy.
Cerchietti LC; Hatzi K; Caldas-Lopes E; Yang SN; Figueroa ME; Morin RD; Hirst M; Mendez L; Shaknovich R; Cole PA; Bhalla K; Gascoyne RD; Marra M; Chiosis G; Melnick A
J Clin Invest; 2010 Dec; 120(12):4569-82. PubMed ID: 21041953
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of histone acetyltransferase function radiosensitizes CREBBP/EP300 mutants via repression of homologous recombination, potentially targeting a gain of function.
Kumar M; Molkentine D; Molkentine J; Bridges K; Xie T; Yang L; Hefner A; Gao M; Bahri R; Dhawan A; Frederick MJ; Seth S; Abdelhakiem M; Beadle BM; Johnson F; Wang J; Shen L; Heffernan T; Sheth A; Ferris RL; Myers JN; Pickering CR; Skinner HD
Nat Commun; 2021 Nov; 12(1):6340. PubMed ID: 34732714
[TBL] [Abstract][Full Text] [Related]
26. Phenotype and genotype in 52 patients with Rubinstein-Taybi syndrome caused by EP300 mutations.
Fergelot P; Van Belzen M; Van Gils J; Afenjar A; Armour CM; Arveiler B; Beets L; Burglen L; Busa T; Collet M; Deforges J; de Vries BB; Dominguez Garrido E; Dorison N; Dupont J; Francannet C; Garciá-Minaúr S; Gabau Vila E; Gebre-Medhin S; Gener Querol B; Geneviève D; Gérard M; Gervasini CG; Goldenberg A; Josifova D; Lachlan K; Maas S; Maranda B; Moilanen JS; Nordgren A; Parent P; Rankin J; Reardon W; Rio M; Roume J; Shaw A; Smigiel R; Sojo A; Solomon B; Stembalska A; Stumpel C; Suarez F; Terhal P; Thomas S; Touraine R; Verloes A; Vincent-Delorme C; Wincent J; Peters DJ; Bartsch O; Larizza L; Lacombe D; Hennekam RC
Am J Med Genet A; 2016 Dec; 170(12):3069-3082. PubMed ID: 27648933
[TBL] [Abstract][Full Text] [Related]
27. Oncogenic Mutations and Tumor Microenvironment Alterations of Older Patients With Diffuse Large B-Cell Lymphoma.
Zhu Y; Fu D; Shi Q; Shi Z; Dong L; Yi H; Liu Z; Feng Y; Liu Q; Fang H; Cheng S; Wang L; Tian Q; Xu P; Zhao W
Front Immunol; 2022; 13():842439. PubMed ID: 35401516
[TBL] [Abstract][Full Text] [Related]
28. Lack of somatic mutations in the catalytic domains of CREBBP and EP300 genes implies a role for histone deacetylase inhibition in myeloproliferative neoplasms.
Andersen CL; Hasselbalch H; Grønbæk K
Leuk Res; 2012 Apr; 36(4):485-7. PubMed ID: 22177454
[TBL] [Abstract][Full Text] [Related]
29. Genetic polymorphism and transcriptional regulation of
Zhao H; Kan Y; Wang X; Chen L; Ge P; Qian Z
Biosci Rep; 2019 Aug; 39(8):. PubMed ID: 31366566
[TBL] [Abstract][Full Text] [Related]
30. Follicular lymphoma, a B cell malignancy addicted to epigenetic mutations.
Korfi K; Ali S; Heward JA; Fitzgibbon J
Epigenetics; 2017 May; 12(5):370-377. PubMed ID: 28106467
[TBL] [Abstract][Full Text] [Related]
31. Tumor-derived Exosomal ENO2 Modulates Polarization of Tumor-associated Macrophages through Reprogramming Glycolysis to Promote Progression of Diffuse Large B-cell Lymphoma.
Shao R; Liu C; Xue R; Deng X; Liu L; Song C; Xie J; Tang H; Liu W
Int J Biol Sci; 2024; 20(3):848-863. PubMed ID: 38250157
[TBL] [Abstract][Full Text] [Related]
32. Diffuse large B-cell lymphoma patient-derived xenograft models capture the molecular and biological heterogeneity of the disease.
Chapuy B; Cheng H; Watahiki A; Ducar MD; Tan Y; Chen L; Roemer MG; Ouyang J; Christie AL; Zhang L; Gusenleitner D; Abo RP; Farinha P; von Bonin F; Thorner AR; Sun HH; Gascoyne RD; Pinkus GS; van Hummelen P; Wulf GG; Aster JC; Weinstock DM; Monti S; Rodig SJ; Wang Y; Shipp MA
Blood; 2016 May; 127(18):2203-13. PubMed ID: 26773040
[TBL] [Abstract][Full Text] [Related]
33. A novel prognostic model based on four circulating miRNA in diffuse large B-cell lymphoma: implications for the roles of MDSC and Th17 cells in lymphoma progression.
Sun R; Zheng Z; Wang L; Cheng S; Shi Q; Qu B; Fu D; Leboeuf C; Zhao Y; Ye J; Janin A; Zhao WL
Mol Oncol; 2021 Jan; 15(1):246-261. PubMed ID: 33107145
[TBL] [Abstract][Full Text] [Related]
34. EP300 facilitates human trophoblast stem cell differentiation.
van Voorden AJ; Keijser R; Veenboer GJM; Lopes Cardozo SA; Diek D; Vlaardingerbroek JA; van Dijk M; Ris-Stalpers C; van Pelt AMM; Afink GB
Proc Natl Acad Sci U S A; 2023 Jul; 120(28):e2217405120. PubMed ID: 37406095
[TBL] [Abstract][Full Text] [Related]
35. Further delineation of an entity caused by CREBBP and EP300 mutations but not resembling Rubinstein-Taybi syndrome.
Menke LA; ; Gardeitchik T; Hammond P; Heimdal KR; Houge G; Hufnagel SB; Ji J; Johansson S; Kant SG; Kinning E; Leon EL; Newbury-Ecob R; Paolacci S; Pfundt R; Ragge NK; Rinne T; Ruivenkamp C; Saitta SC; Sun Y; Tartaglia M; Terhal PA; van Essen AJ; Vigeland MD; Xiao B; Hennekam RC
Am J Med Genet A; 2018 Apr; 176(4):862-876. PubMed ID: 29460469
[TBL] [Abstract][Full Text] [Related]
36. MYC-Mediated Ribosomal Gene Expression Sensitizes Enzalutamide-resistant Prostate Cancer Cells to EP300/CREBBP Inhibitors.
Furlan T; Kirchmair A; Sampson N; Puhr M; Gruber M; Trajanoski Z; Santer FR; Parson W; Handle F; Culig Z
Am J Pathol; 2021 Jun; 191(6):1094-1107. PubMed ID: 33705753
[TBL] [Abstract][Full Text] [Related]
37. E3 ligase FBXW7 restricts M2-like tumor-associated macrophage polarization by targeting c-Myc.
Zhong L; Zhang Y; Li M; Song Y; Liu D; Yang X; Yang D; Qu H; Lai L; Wang Q; Chen Z
Aging (Albany NY); 2020 Dec; 12(23):24394-24423. PubMed ID: 33260160
[TBL] [Abstract][Full Text] [Related]
38. The Role of CREBBP/EP300 and Its Therapeutic Implications in Hematological Malignancies.
Zhu Y; Wang Z; Li Y; Peng H; Liu J; Zhang J; Xiao X
Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831561
[TBL] [Abstract][Full Text] [Related]
39. Identifying collagen VI as a target of fibrotic diseases regulated by CREBBP/EP300.
Williams LM; McCann FE; Cabrita MA; Layton T; Cribbs A; Knezevic B; Fang H; Knight J; Zhang M; Fischer R; Bonham S; Steenbeek LM; Yang N; Sood M; Bainbridge C; Warwick D; Harry L; Davidson D; Xie W; Sundstrӧm M; Feldmann M; Nanchahal J
Proc Natl Acad Sci U S A; 2020 Aug; 117(34):20753-20763. PubMed ID: 32759223
[TBL] [Abstract][Full Text] [Related]
40. Rubinstein-Taybi syndrome in a Saudi boy with distinct features and variants in both the CREBBP and EP300 genes: a case report.
Al-Qattan MM; Jarman A; Rafique A; Al-Hassnan ZN; Al-Qattan HM
BMC Med Genet; 2019 Jan; 20(1):12. PubMed ID: 30635043
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
